Valley National Advisers’s Charles River Laboratories CRL Stock Holding History

Valley National Advisers’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8	Closed	-$1K	–	1226
2023 Q4	$1K	Buy	8 +1	+14%	+$197	﹤0.01%	1045
2023 Q3	$1K	Hold	7	–	–	﹤0.01%	903
2023 Q2	$2K	Hold	7	–	–	﹤0.01%	776
2023 Q1	$1K	Hold	7	–	–	﹤0.01%	802
2022 Q4	$1K	Hold	7	–	–	﹤0.01%	778
2022 Q3	$1K	Hold	7	–	–	﹤0.01%	826
2022 Q2	$2K	Hold	7	–	–	﹤0.01%	755
2022 Q1	$2K	Hold	7	–	–	﹤0.01%	787
2021 Q4	$3K	Hold	7	–	–	﹤0.01%	738
2021 Q3	$3K	Hold	7	–	–	﹤0.01%	720
2021 Q2	$3K	Hold	7	–	–	﹤0.01%	732
2021 Q1	$2K	Hold	7	–	–	﹤0.01%	723
2020 Q4	$2K	Hold	7	–	–	﹤0.01%	683
2020 Q3	$2K	Hold	7	–	–	﹤0.01%	649
2020 Q2	$1K	Hold	7	–	–	﹤0.01%	701
2020 Q1	$1K	Buy	+7	New	+$1.05K	﹤0.01%	682

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Valley National Advisers's CRL Position: Q1 2024 in Review

Valley National Advisers sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 8 shares — an estimated $1K sold.

Valley National Advisers first reported a position in CRL in Q1 2020 and held it in 16 quarters. The position peaked at $3K in Q4 2021. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

Valley National Advisers reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
Valley National Advisers sold 8 Charles River Laboratories shares in Q1 2024, an estimated $1K.
Valley National Advisers first reported a position in Charles River Laboratories in Q1 2020 and held it in 16 quarters.
Valley National Advisers's Charles River Laboratories position peaked at $3K in Q4 2021.
676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Valley National Advisers's 13F filing for Q1 2024, filed 19 Apr 2024.